| Document and Entity Information | Nov. 01, 2024 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Nov. 01, 2024 |
| Entity File Number | 001-36297 |
| Entity Registrant Name | Revance Therapeutics, Inc. |
| Entity Central Index Key | 0001479290 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 77-0551645 |
| Entity Address, Address Line One | 1222 Demonbreun Street |
| Entity Address, Address Line Two | Suite 2000 |
| Entity Address, City or Town | Nashville |
| Entity Address, State or Province | TN |
| Entity Address, Postal Zip Code | 37203 |
| City Area Code | 615 |
| Local Phone Number | 724-7755 |
| Title of 12(b) Security | Common Stock, $0.001 par value |
| Trading Symbol | RVNC |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
